Stay up to date on the latest oncology and nursing conferences.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Standard-of-Care HRRm Testing Underutilized in Patients With mCRPC
January 25th 2024Despite germline and somatic testing being the standard of care for patients with metastatic castration-resistant prostate cancer, rates of its real-world use shows that it may be underutilized, which may negatively impact therapeutic offerings.
Darolutamide Plus ADT May Lower Hospitalization Rates, Slightly Prolong Stays in mHSPC
January 25th 2024Darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer may lower hospitalization rates but marginally longer lengths of stay vs treatment with placebo, androgen deprivation therapy, and docetaxel.
Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC
January 20th 2024Patients with advanced hepatocellular carcinoma treated with frontline pembrolizumab plus lenvatinib showed a 3-year or more response among 35% of responders, although additional efficacy results from the trial are consistent with previous findings from the phase 3 LEAP-002 trial.
Patients With ESCC Derive Survival Benefit With Tiragolumab Plus Atezolizumab and Chemotherapy
January 20th 2024Patients with esophageal squamous cell carcinoma obtained significant survival improvements when treated with tiragolumab plus atezolizumab and chemotherapy compared with chemotherapy alone.
Adding Nivolumab to Chemo Increases OS, PFS in Previously Untreated Advanced GI Cancers
January 19th 2024Overall survival and progression-free survival improves with nivolumab plus chemotherapy compared with chemotherapy alone in the overall population and in patients with a PD-L1 CPS of 5 or greater.
HER2+ Breast Cancer May Respond to Neoadjuvant HER2 Blockade Plus Polychemotherapy
January 16th 2024Treatment with pegylated liposomal doxorubicin and cyclophosphamide in the neoadjuvant setting, followed by a taxane, in addition to trastuzumab and pertuzumab, resulted in antitumor activity in patients with HER2-positive breast cancer.
Pirtobrutinib Generates Durable Responses in CLL/SLL After BTKi Therapy
December 11th 2023The use of pirtobrutinib following covalent Bruton tyrosine kinase inhibitor therapy may be an important sequencing approach in chronic lymphocytic leukemia/small lymphocytic lymphoma, according to recent research.